{
    "clinical_study": {
        "@rank": "105702", 
        "acronym": "VAROCE", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "Docetaxel + Nintedanib"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Active Comparator", 
                "description": "Docetaxel + increase of the dose"
            }
        ], 
        "brief_summary": {
            "textblock": "Second-line chemotherapy for metastatic or locally recurrent breast cancer"
        }, 
        "brief_title": "Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Locally Recurrent or Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18 years old\n\n          -  Histologically or cytologically confirmed adenocarcinoma of the breast\n\n          -  Locally recurrent or metastatic disease\n\n          -  HER 2 negative status\n\n          -  Prior first line chemotherapy not containing Docetaxel\n\n          -  Relapsing after a first line chemotherapy for locally recurrent or metastatic disease\n\n          -  Measurable or evaluable disease according to RECIST criteria\n\n          -  Prior chemotherapy as follows :\n\n               -  Docetaxel in the neoadjuvant or adjuvant setting is allowed provided that\n                  relapse has been observed more than 12 months after the end of docetaxel\n                  treatment\n\n               -  Bevacizumab in 1st line is allowed with a wash-out of 3 months\n\n          -  ECOG performance status 0-1\n\n          -  Adequate bone marrow, hepatic and renal functions as evidence by the following:\n\n               -  Hemoglobin \u2265 10 G/100 mL\n\n               -  Neutrophils count  \u2265 1500 /mm3\n\n               -  Platelets \u2265 100 000 /mm3\n\n               -  Total bilirubin \u2264 ULN (ULN:Upper Limit of Normal)\n\n               -  SGOT/SGPT \u2264 1.5 x ULN (\u2264 2.5 x ULN in case of hepatic metastasis)\n\n               -  Creatinin clearance \u2265 45 ml/min or creatinin \u2264 1.5 x ULN\n\n               -  Proteinuria < CTCAE grade 2\n\n          -  Coagulation parameters: International normalised ratio (INR) \u2264 2, prothrombin time\n             (PT) and partial thromboplastin time (PTT) \u2264 50% of deviation  of institutional ULN\n\n          -  Effective contraception for patients (male and female) of reproductive potential\n             during their entire participation in the study and during 3 months after the last\n             administration of Nintedanib or Docetaxel\n\n          -  Negative pregnancy test (serum beta-HCG) within 1 week prior to start of study\n             treatment in females of reproductive potential\n\n          -  Patient covered by government health insurance\n\n          -  Signed and dated written informed consent prior to  admission to the study in\n             accordance with ICH-GCP guidelines and to the local legislation\n\n        Exclusion Criteria:\n\n          -  Symptomatic brain metastasis\n\n          -  Concomitant hormone therapy for metastatic breast cancer\n\n          -  Patients with dysphagia, or inability to swallow the tablets\n\n          -  Other serious illness or medical conditions: Cardiac disease\n\n          -  Unstable diabetes\n\n          -  Uncontrolled hypercalcemia\n\n          -  Clinically significant active infections\n\n          -  Pregnancy or breast feeding woman\n\n          -  Unable for medical follow-up (geographic, social or mental reasons)\n\n          -  Prior treatment with Nintedanib or any other VEGFR inhibitor or stratify if trial\n             aims to establish anti-angiogenic retreatment\n\n          -  Known hypersensitivity to the trial drugs , to their excipients or to contrast media\n\n          -  Contra indication to the use of the backbone treatment and to the comparator\n\n          -  Active brain metastases (e.g. stable for <4 weeks, no adequate previous treatment\n             with radiotherapy, symptomatic, requiring treatment with anti-convulsants;\n             dexamethasone therapy will be allowed if administered as stable dose for at least one\n             month before randomisation)\n\n          -  Leptomeningeal disease\n\n          -  Radiographic evidence of cavitary or necrotic tumors\n\n          -  Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of\n             major blood vessels\n\n          -  History of clinically significant haemorrhagic or thromboembolic event in the past 6\n             months\n\n          -  Known inherited predisposition to bleeding or thrombosis\n\n          -  Significant cardiovascular diseases ( i.e. uncontrolled hypertension, unstable\n             angina, history of infarction within the past 12 months prior to  start of study\n             treatment, congestive heart failure > NYHA II, serious cardiac arrhythmia,\n             pericardial effusion)\n\n          -  Other malignancies within the past 5 years other than basal cell skin cancer or\n             carcinoma in situ of the cervix\n\n          -  Active serious infections in particular if requiring systemic antibiotic or\n             antimicrobial therapy\n\n          -  Active or chronic hepatitis C and/or B infection\n\n          -  Active alcohol or drug abuse\n\n          -  Significant weight loss (> 10% of BW) within past 6 months prior to inclusion into\n             the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01658462", 
            "org_study_id": "VAROCE - 1206"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B"
                ], 
                "description": "75 mg/m2 IV Day 1 / 3 weeks Arm B : dose can be increased to 100 mg/m2 secondarily on cycle 2", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm A", 
                "description": "200 mg x 2 per os daily No Nintedanib on days when docetaxel is administered", 
                "intervention_name": "Nintedanib", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Docetaxel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breast cancer", 
            "Docetaxel", 
            "Nintedanib"
        ], 
        "lastchanged_date": "August 5, 2013", 
        "location": [
            {
                "contact": {
                    "email": "pipro.christine@chu-amiens.fr", 
                    "last_name": "Christine PIPROT, MD", 
                    "phone": "+33 (0)3.22.45.56.99"
                }, 
                "facility": {
                    "address": {
                        "city": "Amiens", 
                        "country": "France", 
                        "zip": "80 054"
                    }, 
                    "name": "South Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Christine PIPROT, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Bruno CHAUFFERT, MD PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cgiraud@clinique-psv.fr", 
                    "last_name": "Claire GIRAULT, MD", 
                    "phone": "+33 (0)3.27.08.60.63"
                }, 
                "facility": {
                    "address": {
                        "city": "Dechy", 
                        "country": "France", 
                        "zip": "59 187"
                    }, 
                    "name": "Leonard de Vinci Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Claire GIRAUD, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Virginie POTTIER, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Nicolas REZVOY, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "j-bonneterre@o-lambret.fr", 
                    "last_name": "Jacques BONNETERRE, MD PhD", 
                    "phone": "+33 (0)3.20.29.55.50"
                }, 
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59 020"
                    }, 
                    "name": "Oscar Lambret Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Jacques BONNETERRE, MD PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Audrey MAILLIEZ, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "V\u00e9ronique SERVENT, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Laurence VANLEMMENS, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "herve.cure@reims.unicancer.fr", 
                    "last_name": "Herv\u00e9 CURE, MDPhD", 
                    "phone": "+33 (0)3.26.50.44.87"
                }, 
                "facility": {
                    "address": {
                        "city": "St HERBLAIN", 
                        "country": "France", 
                        "zip": "44 805"
                    }, 
                    "name": "West Cancerology Institut"
                }, 
                "investigator": [
                    {
                        "last_name": "Herv\u00e9 CURE, MDPhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Christelle JOUANNAUD, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "J-Christophe EYMARD, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Aude-Marie SAVOYE, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Gabriel YAZBEK, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Brigitte COSTA, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "m.rios@nancy.unicancer.fr", 
                    "last_name": "Maria RIOS, MD", 
                    "phone": "+33 (0)3.83.59.85.66"
                }, 
                "facility": {
                    "address": {
                        "city": "Vandoeuvre Les Nancy", 
                        "country": "France", 
                        "zip": "54 500"
                    }, 
                    "name": "Alexis Vautrin Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Maria ROSS, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Mathilde DEBLOCK, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II Randomized Study of Docetaxel With or Without NINTEDANIB (BIBF-1120) in Patient Receiving a Second-line of Chemotherapy for HER Negative Metastatic or Locally Recurrent Breast Cancer", 
        "overall_contact": {
            "email": "j-bonneterre@o-lambret.fr", 
            "last_name": "Jacques BONNETERRE, MD PhD", 
            "phone": "+33 (0)3.20.29.55.50"
        }, 
        "overall_official": {
            "affiliation": "Oscar Lambret Center", 
            "last_name": "Jacques BONNETERRE, MD PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Committee for the Protection of Personnes", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "6-months progression free disease", 
            "measure": "increase in the progression free survival (PFS) in patients receiving Docetaxel + Nintedanib treatment (Arm A)  compared to Docetaxel alone (Arm B)", 
            "safety_issue": "Yes", 
            "time_frame": "baseline, every 3 weeks, up to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01658462"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "according to RECIST 1.1", 
                "measure": "response rate", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, every 3 weeks, up to 6 months"
            }, 
            {
                "description": "time from the date of randomization to the date of death from any cause", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }, 
            {
                "description": "EORTC QLQ C30 (Additional module BR23)", 
                "measure": "quality of life", 
                "safety_issue": "No", 
                "time_frame": "baseline, every 3 weeks, up to 6 months"
            }, 
            {
                "description": "biological analysis of cells RT-qPCR analysis, including endothelial cells using a specific reference gene", 
                "measure": "biological markers levels in tumors and endothelial cells", 
                "safety_issue": "No", 
                "time_frame": "baseline, every 9 weeks, up to 6 months"
            }, 
            {
                "description": "biological analysis in patient's serum Dosage of VEGF-A, -C, FGF-1, -2, PDGF-AA, -AB, -BB in patient's serum", 
                "measure": "biological markers in patient serum", 
                "safety_issue": "No", 
                "time_frame": "baseline, every 9 weeks, up to 6 months"
            }
        ], 
        "source": "Centre Oscar Lambret", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Oscar Lambret", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}